Article

OASIS, AJL Ophthalmic to distribute corneal implants

OASIS Medical Inc. and Spain-based AJL Ophthalmic SA have announced an exclusive relationship for the sales and distribution of corneal implants (Intacs) for the treatment of keratoconus and the FDA-approved treatment of myopia.

 

Glendora, CA-OASIS Medical Inc. and Spain-based AJL Ophthalmic SA have announced an exclusive relationship for the sales and distribution of corneal implants (Intacs) for the treatment of keratoconus and the FDA-approved treatment of myopia.

Addition Technologies, acquired by AJL Ophthalmic in January 2013, will continue the manufacturing and remain the FDA-approved Humanitarian Device Exemption holder of the device.

“OASIS is honored to work with AJL Ophthalmic and the (device),” said Craig Delgado, president of OASIS. “(This corneal implant) serves keratoconus patients, giving them a truly extraordinary option to retain their visual acuity once contacts or glasses are no longer a viable option.”

 

For more articles in this issue of Ophthalmology Times eReport, click here.

 

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.